 BEIJING--BUSINESS WIRE--Sinovac Biotech Ltd. NASDAQ: SVA Sinovac or the Company, a leading provider of biopharmaceutical products in China, today announced phase III results. Sinovac had started its phase III trials on CoronaVac, its COVID-19 vaccine, on July 21, 2020. Trials were conducted in Brazil, Turkey, Indonesia, and Chile. In compliance with the principles of Good Clinical Practice GCP, the trials were conducted with the vaccine candidate produced from the same lot and follo 